GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (AMEX:ARMP) » Definitions » Shiller PE Ratio

Armata Pharmaceuticals (Armata Pharmaceuticals) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Armata Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Armata Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Armata Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals Shiller PE Ratio Chart

Armata Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Armata Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Armata Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Armata Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Armata Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Shiller PE Ratio falls into.



Armata Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Armata Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Armata Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.69/131.7762*131.7762
=-0.690

Current CPI (Mar. 2024) = 131.7762.

Armata Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 292.598 100.560 383.429
201409 461.997 100.428 606.209
201412 -820.395 99.070 -1,091.237
201503 -488.597 99.621 -646.303
201506 46.200 100.684 60.467
201509 -42.000 100.392 -55.130
201512 -75.600 99.792 -99.830
201603 -115.079 100.470 -150.937
201606 -109.479 101.688 -141.872
201609 -45.220 101.861 -58.501
201612 -106.399 101.863 -137.645
201703 -27.160 102.862 -34.795
201706 -20.440 103.349 -26.062
201709 -1.260 104.136 -1.594
201712 -0.560 104.011 -0.709
201803 -3.360 105.290 -4.205
201806 -2.660 106.317 -3.297
201809 -0.600 106.507 -0.742
201812 1.513 105.998 1.881
201903 -0.800 107.251 -0.983
201906 -0.690 108.070 -0.841
201909 -0.730 108.329 -0.888
201912 -0.480 108.420 -0.583
202003 -0.490 108.902 -0.593
202006 -0.260 108.767 -0.315
202009 -0.310 109.815 -0.372
202012 -0.360 109.897 -0.432
202103 -0.270 111.754 -0.318
202106 -0.250 114.631 -0.287
202109 -0.220 115.734 -0.250
202112 -0.230 117.630 -0.258
202203 -0.300 121.301 -0.326
202206 -0.260 125.017 -0.274
202209 -0.240 125.227 -0.253
202212 -0.290 125.222 -0.305
202303 -0.400 127.348 -0.414
202306 -0.170 128.729 -0.174
202309 -0.860 129.860 -0.873
202312 -0.550 129.419 -0.560
202403 -0.690 131.776 -0.690

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Armata Pharmaceuticals  (AMEX:ARMP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Armata Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Armata Pharmaceuticals (Armata Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Executives
Richard Rychlik officer: Corporate Controller and PFO 5005 MCCONNELL AVENUE, LOS ANGELES CA 90066
Deborah Birx director, officer: Chief Executive Officer 3300 LOWELL STREET NW, WASHINGTON DC 20008
Julianne Averill officer: Chief Financial Officer 361 NEWBURY STREET, SUITE 500, BOSTON MA 02115
Erin Butler officer: Vice President,Finance & Admin 4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110
Theravance Inc director, 10 percent owner 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Innoviva Strategic Opportunities Llc director, 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801
Robin Kramer director 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109
Steven Robert Martin officer: Chief Financial Officer 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Todd C. Peterson director C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292
H Stewart Parker director

Armata Pharmaceuticals (Armata Pharmaceuticals) Headlines

From GuruFocus